Physician profile
Devendra C Shah
NPI 1164418125
$23,577.01
in general payments reported to CMS, 2019-2025
34 companies · $2,181 in 2025
The $2,181 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $1,569 · 2021: $1,860 · 2022: $2,221 · 2023: $2,301 · 2024: $2,478 · 2025: $2,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,843 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,842.97 |
| Education | $117.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $8,913.61 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,788.49 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,757.40 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,721.23 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,359.06 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Janssen Pharmaceuticals, INC | $1,297.21 | 2019-2025 | Invega Sustenna |
| Bausch Health US, LLC | $649.93 | 2019-2025 | Aplenzin, Wellbutrin |
| Supernus Pharmaceuticals, INC. | $620.62 | 2021-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $533.16 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $476.06 | 2019-2025 | Trintellix |
| Abbvie INC. | $435.52 | 2021-2025 | Vraylar |
| Allergan, INC. | $416.11 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $381.48 | 2019-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $352.40 | 2019-2025 | Rexulti |
| Neos Therapeutics, Lp | $303.80 | 2019-2024 | Adzenys Xr-Odt |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $250.14 | 2019-2023 | Dyanavel Xr |
| Noven Therapeutics, LLC | $248.33 | 2021-2025 | Xelstrym, Secuado |
| Neuronetics, INC. | $242.39 | 2024-2025 | Neurostar Tms Therapy System |
| Eisai INC. | $218.41 | 2020-2021 | |
| Indivior INC. | $216.64 | 2019-2024 | Perseris, Sublocade |
| E.R. Squibb & Sons, L.L.C. | $213.81 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $205.26 | 2023-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $182.77 | 2019-2023 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $162.26 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $153.61 | 2020-2022 | |
| Almatica Pharma LLC | $114.63 | 2021-2024 | Loreev Xr |
| Avanir Pharmaceuticals, INC. | $90.28 | 2019-2020 | |
| Adlon Therapeutics L.P. | $87.88 | 2019-2021 | |
| Corium, LLC | $56.82 | 2022-2023 | Azstarys |
| Arbor Pharmaceuticals, INC. | $33.30 | 2019 | |
| Jazz Pharmaceuticals INC. | $33.01 | 2019-2020 | |
| Bioxcel Therapeutics, INC. | $23.63 | 2023 | Igalmi |
| Noven Pharmaceuticals, INC. | $21.20 | 2024 | Xelstrym |
| Vertical Pharmaceuticals, LLC | $16.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devendra Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.